Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant milestone for Dechra Pharmaceuticals-B (德琪医药-B), enhancing its market presence and competitiveness in the biopharmaceutical sector [1] Group 1: Company Developments - Dechra Pharmaceuticals-B's stock rose nearly 6%, with a current price of 4.34 HKD and a trading volume of 9.4944 million HKD [1] - The approved applications are for the treatment of multiple myeloma (in combination with Bortezomib and Dexamethasone for adult patients who have received at least one prior therapy) and relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not candidates for hematopoietic stem cell transplantation) [1] Group 2: Market Implications - The approvals signify Dechra Pharmaceuticals-B's further expansion in the Hong Kong market, which is crucial for the company's business development [1] - The launch of Selinexor is expected to meet the treatment needs for relevant diseases in the Hong Kong market, thereby enhancing the company's competitiveness in the biotechnology industry [1]
港股异动 | 德琪医药-B(06996)涨近6% 希维奥两项补充新药申请获香港卫生署批准